Case study

Supporting first lyophilised mRNA vaccine to pivotal trial

SFF

Recipharm helped Arcturus meet its supply needs for its Phase III trial by lyophilising ARCT-154, a promising next-generation self-amplifying mRNA COVID-19 vaccine candidate.

To read our case study please complete your details below:

First Name

Last Name

Company

Where are you based?

State/Province

I agree that Recipharm registers the above information and gives me information about services and products via email. Read more about our Privacy Policy

Hidden OSD

Hidden SFF

Hidden ADS

Hidden BU not set